Ribavirin has been widely used for the treatment of HCV chronic hepatitis of non-immunocompromised patients and, lately, it has been used even in liver or kidney transplant patients. A 51 y.o. male with a 8-year history of well functioning renal transplant (creatinine 1.6 mg/dl) developed abiopsy-proven HCV-related chronic active hepatitis with marked cholestasis and histological findings of periportal bridging. After ribavirin treatment at a daily dosage of 600 mg p.o. a normalization of cholestatic indexes was detected with a negative PCR-RNA HCV. After 18 months of treatment no relevant side effects was detected and the renal function remained stable.
A 18-months ribavirin treatment for cholestatic chronic HCV-related hepatitis in a kidney transplant patient
Manna C.;La Manna G.;Casanova S.;Stefoni S.;Bonomini V.
1998
Abstract
Ribavirin has been widely used for the treatment of HCV chronic hepatitis of non-immunocompromised patients and, lately, it has been used even in liver or kidney transplant patients. A 51 y.o. male with a 8-year history of well functioning renal transplant (creatinine 1.6 mg/dl) developed abiopsy-proven HCV-related chronic active hepatitis with marked cholestasis and histological findings of periportal bridging. After ribavirin treatment at a daily dosage of 600 mg p.o. a normalization of cholestatic indexes was detected with a negative PCR-RNA HCV. After 18 months of treatment no relevant side effects was detected and the renal function remained stable.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
